Traditionally, empirical methods are used in the life-science industry to discover new drugs. Therapeutic effectiveness or bioavailability is determined mostly by trial and error - even today. However, rational discovery of drugs is beginning to revolutionize the industry. Unfortunately, the same cannot be said for the manufacturing of the final drug product - despite the fact that drugs are complex products, with a number of engineered features. Also, new drugs coming to the market are larger molecules, which are designed to be a complex, three-dimensional molecule to targets specific enzymes or cell surface receptors.
This current trend is called the advent of the "large-molecule drugs". Large-molecule drugs, however, have one setback. They are difficult to make, and often it is nearly impossible to deliver them to the body. Thus, significant scientific know-how and expertise is required to make a drug into a product, i.e., there is a compelling need to apply engineering and science principles to this industry. The proposed program of the Marie Curie Chair (MCC) addresses exactly this issue, i.e., how to make a product from a newly discovered molecule. The research program will be a unique, multi-disciplinary combination of quantum-computational chemistry, experimental chiral catalysis, molecular design, and cutting-edge computer DNS simulations of multi-phase reactive flows in pharmaceutical processes.
The MCC also proposes a strong educational program combined with out-reach initiatives to disseminate his work to a broad audience, and to train young researches in a relevant and new area. This initiative lies also well within the scope of the Graz University of Technology to form a Life-Science Engineering Centre that includes areas such as advanced material s, bio-catalysis, reaction and bio-engineering, and nano-technology. In all activities the MCC will specifically address the need to foster women in science and engineering, as he has done in the past.
Call for proposal
See other projects for this call